Hester Biosciences Analysis

dividend

Pros

• Dividends per share have increased over the past 10 years.
• Dividends paid are well covered by earnings (4.4x coverage).
• Hester Biosciences's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).

Cons

• Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
• Hester Biosciences's dividend is below the markets top 25% of dividend payers in India (3.08%).

health

Pros

• Hester Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Hester Biosciences is profitable, therefore cash runway is not a concern.
• Hester Biosciences is profitable, therefore cash runway is not a concern.
• Debt is well covered by operating cash flow (56.4%, greater than 20% of total debt).
• Debt is covered by short term assets, assets are 1.5x debt.
• Hester Biosciences's cash and other short term assets cover its long term commitments.
• The level of debt compared to net worth has been reduced over the past 5 years (62.1% vs 56.5% today).
• Interest payments on debt are well covered by earnings (EBIT is 10.8x coverage).

Cons

• Hester Biosciences's level of debt (56.5%) compared to net worth is high (greater than 40%).
• High level of physical assets or inventory.

management

Pros

• The tenure for the Hester Biosciences board of directors is about average.
• Rajiv's compensation has been consistent with company performance over the past year, both up more than 20%.
• The tenure for the Hester Biosciences management team is about average.

Cons

• Rajiv's remuneration is higher than average for companies of similar size in India.

misc

Pros

Cons

• Hester Biosciences is not covered by any analysts.

past

Pros

• Hester Biosciences has delivered over 20% year on year earnings growth in the past 5 years.
• Hester Biosciences used its assets more efficiently than the IN Biotechs industry average last year based on Return on Assets.
• Hester Biosciences has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
• Hester Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
• Hester Biosciences's earnings growth has exceeded the Asia Biotechs industry average in the past year (5.2% vs -5.4%).

Cons

• Hester Biosciences's 1-year earnings growth is less than its 5-year average (5.2% vs 20.4%)

value

Pros

• Hester Biosciences is good value based on earnings compared to the IN Biotechs industry average.

Cons

• Hester Biosciences's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
• Hester Biosciences's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
• Hester Biosciences is overvalued based on assets compared to the IN Biotechs industry average.
• Hester Biosciences is overvalued based on earnings compared to the India market.
• 524669 underperformed the Biotechs industry which returned 53.2% over the past year.
• 524669 underperformed the Market in India which returned -14.5% over the past year.
• BSE:524669 is up 6.2% underperforming the Biotechs industry which returned 18.2% over the past month.
• BSE:524669 is up 6.2% underperforming the market in India which returned 8% over the past month.